OncoMatch/Clinical Trials/NCT05564377
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Is NCT05564377 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for advanced malignant solid neoplasm.
Treatment: Alpelisib · Binimetinib · Fluorouracil · Fulvestrant · Ipatasertib · Leucovorin · Neratinib Maleate · Nilotinib Hydrochloride Monohydrate · Olaparib · Oxaliplatin · Paclitaxel · Palbociclib · Panitumumab · Selumetinib Sulfate · Sotorasib — This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Endocrine / hormonal
Other
Cancer type
Tumor Agnostic
Breast Carcinoma
Endometrial Cancer
Ovarian Cancer
Disease stage
Required: Stage III, STAGE III, STAGE IV, IV (AJCC v8)
Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- University of South Alabama Mitchell Cancer Institute · Mobile, Alabama
- Alaska Women's Cancer Care · Anchorage, Alaska
- CTCA at Western Regional Medical Center · Goodyear, Arizona
- Kingman Regional Medical Center · Kingman, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05564377 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III or STAGE III or STAGE IV or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages